DOCSLIB.ORG

RESEARCH HIGHLIGHTS Spironolactone and Hyperkalemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RESEARCH HIGHLIGHTS Spironolactone and Hyperkalemia RESEARCH HIGHLIGHTS www.nature.com/clinicalpractice/cardio and safety of DES (with sirolimus or paclitaxel) patients with heart failure who were treated GLOSSARY and BMS. All trials provided 6–12 months' clini- with ACE inhibitors, there were 560 additional ECG Electrocardiogram cal follow-up after index PCI. Using a hierarchi- hospitalizations for hyperkalemia (95% CI 285 cal Bayesian random-effects model, the team to 754) and 73 additional inpatient deaths pooled the results, stratifying by the type of (95% CI 27 to 120) in 2001, compared with the drug and presence of carrier polymer. expected numbers. The pooled results indicated that mortality In conclusion, publication of RALES was and MI occurred at similar rates for DES and associated with a sharp increase in the spironol- BMS. Major cardiac adverse events, however, actone prescription rate, in the rate of hospi- occurred at a lower rate in the DES group than talization for hyperkalemia and in associated in the BMS patients (7.8% vs 16.4%; odds mortality. The authors suggest that clinicians ratio (OR) 0.42; 95% credible interval (CI) 0.32 should take into account other risk factors for to 0.53), as did angiographic restenosis (8.9% hyperkalemia when prescribing spironolactone, vs 29.3%; OR 0.18; 95% CI 0.06 to 0.40). and that renal function and potassium levels The authors conclude that sirolimus-eluting should be closely monitored. and polymeric-paclitaxel-eluting stents are superior to BMS in reducing the rates of angio- Original article Juurlink DN et al. (2004) Rates of hyperkalemia after publication of the randomized aldactone graphic restenosis and major cardiac adverse evaluation study. N Engl J Med 351: 543–551 events, although no clear benefit has been shown in terms of a reduction in mortality or MI rates. Prediction of outcome in Original article Babapulle MN et al. (2004) A hierarchical myocardial ischemia Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364: 583–591 A report by Mueller and colleagues has provided new information about the prognostic value of the admission ECG in cases of myocardial ischemia. Spironolactone and hyperkalemia The study included a cohort of 1,450 consecutive patients with unstable angina/non-ST-segment The landmark Randomized Aldactone Evaluation elevation myocardial infarction (nonSTEMI), who Study (RALES), published in 1999, showed that were assessed by coronary angiography within spironolactone, a potassium-sparing diuretic, 24 h of admission. Patients were divided into improves outcomes in patients with severe three groups according to the presence of new heart failure. The drug can sometimes cause ST-segment depression (n = 136), T-wave inver- life-threatening hyperkalemia, however, when sion (n = 419) or no changes on the admission used in combination with angiotensin-convert- ECG (n = 895). Revascularization was carried out ing enzyme (ACE) inhibitors (which are also in the majority of patients (n = 1,066), most often indicated for heart failure). Although this com- by percutaneous coronary intervention (PCI) with plication was rare in RALES, it is possible that stent placement. Coronary artery bypass grafting physicians prescribe spironolactone more freely was carried out in selected patients. The primary in practice. Juurlink et al. have carried out a time- endpoint was all-cause mortality. series analysis to examine the effects of RALES Adjusting for potential confounders, the cumu- at the population level in Ontario, Canada. lative death rate at 36 months was significantly For the period 1994–2001, the investigators higher for patients with ST-segment depression linked the records of all prescription drugs (hazard ratio [HR] 2.2, 95% CI 1.1 to 4.6) than dispensed and all hospitalizations for over for patients with no ECG changes; by contrast, 1.3 million patients aged 66 years or older. They T-wave inversion was associated with a more examined trends in spironolactone-prescribing favorable outcome (HR 0.44, 95% CI 0.20 to rates, hospitalization for hyperkalemia and 0.96). Surprisingly, the prognostic value of these associated mortality. ECG changes was similar in men and women. From 1994 to 2001, there was a statisti- Mueller et al. conclude that ST-segment cally significant increase (P < 0.001) in rates of depression and T-wave inversion were impor- spironolactone prescription, hospitalization for tant prognostic factors in patients undergoing hyperkalemia and associated mortality. Among very early revascularization for unstable angina/ NOVEMBER 2004 VOL 1 NO 1 NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE 5.
Load more

Recommended publications
  • PPE Requirements Hazardous Drug Handling
    This document’s purpose is only to provide general guidance. It is not a definitive interpretation for how to comply with DOSH requirements. Consult the actual NIOSH hazardous drugs list and program regulations in entirety to understand all specific compliance requirements. Minimum PPE Required Minimum PPE Required Universal (Green) - handling and disposed of using normal precautions. PPE Requirements High (Red) - double gloves, gown, eye and face protection in Low (Yellow) - handle at all times with gloves and appropriate engineering Hazardous Drug Handling addition to any necessary controls. engineering controls. Moderate (Orange) -handle at all times with gloves, gown, eye and face protection (with splash potential) and appropirate engineering controls. Tablet Open Capsule Handling only - Contained Crush/Split No alteration Crush/Split Dispensed/Common Drug Name Other Drug Name Additional Information (Formulation) and (NIOSH CATEGORY #) Minimum PPE Minimum PPE Minimum PPE Minimum PPE Required required required required abacavir (susp) (2) ziagen/epzicom/trizivir Low abacavir (tablet) (2) ziagen/epzicom/trizivir Universal Low Moderate acitretin (capsule) (3) soriatane Universal Moderate anastrazole (tablet) (1) arimidex Low Moderate High android (capsule) (3) methyltestosterone Universal Moderate apomorphine (inj sq) (2) apomorphine Moderate arthotec/cytotec (tablet) (3) diclofenac/misoprostol Universal Low Moderate astagraf XL (capsule) (2) tacrolimus Universal do not open avordart (capsule) (3) dutasteride Universal Moderate azathioprine
    [Show full text]
  • 1 Fluid and Elect. Disorders of Serum Sodium Concentration
    DISORDERS OF SERUM SODIUM CONCENTRATION Bruce M. Tune, M.D. Stanford, California Regulation of Sodium and Water Excretion Sodium: glomerular filtration, aldosterone, atrial natriuretic factors, in response to the following stimuli. 1. Reabsorption: hypovolemia, decreased cardiac output, decreased renal blood flow. 2. Excretion: hypervolemia (Also caused by adrenal insufficiency, renal tubular disease, and diuretic drugs.) Water: antidiuretic honnone (serum osmolality, effective vascular volume), renal solute excretion. 1. Antidiuresis: hyperosmolality, hypovolemia, decreased cardiac output. 2. Diuresis: hypoosmolality, hypervolemia ~ natriuresis. Physiologic changes in renal salt and water excretion are more likely to favor conservation of normal vascular volume than nonnal osmolality, and may therefore lead to abnormalities of serum sodium concentration. Most commonly, 1. Hypovolemia -7 salt and water retention. 2. Hypervolemia -7 salt and water excretion. • HYFERNATREMIA Clinical Senini:: Sodium excess: salt-poisoning, hypertonic saline enemas Primary water deficit: chronic dehydration (as in diabetes insipidus) Mechanism: Dehydration ~ renal sodium retention, even during hypernatremia Rapid correction of hypernatremia can cause brain swelling - Management: Slow correction -- without rapid administration of free water (except in nephrogenic or untreated central diabetes insipidus) HYPONA1REMIAS Isosmolar A. Factitious: hyperlipidemia (lriglyceride-plus-plasma water volume). B. Other solutes: hyperglycemia, radiocontrast agents,. mannitol.
    [Show full text]
  • Study Guide Medical Terminology by Thea Liza Batan About the Author
    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
    [Show full text]
  • Drug-Induced Sexual Dysfunction in Men and Women
    VOLUME 36 : NUMBER 2 : APRIL 2013 ARTICLE Drug-induced sexual dysfunction in men and women Helen M Conaglen whether the clinician is willing to ask about sexual Clinical psychologist and SUMMARY issues and does so in a sensitive way.7,8 Senior research fellow Many medical conditions and their treatments Patients on long-term medications may not be John V Conaglen aware that their sexual problems have developed Endocrinologist and contribute to sexual dysfunction. as a result of their treatment. Conversely some may Associate professor in Commonly implicated drugs include Medicine blame their drugs for sexual problems which are due Sexual Health Research Unit antihypertensives, antidepressants, to relationship difficulties or other stressors. Some Waikato Clinical School antipsychotics and antiandrogens. doctors consider that asking patients if they had Faculty of Medical and Understanding the potential for drug-induced noticed any sexual adverse effects from their drugs Health Sciences University of Auckland sexual problems and their negative impact may ‘suggest’ them to the patient, and possibly result on adherence to treatment will enable the in non-adherence. Patients attributing their sexual clinician to tailor treatments for the patient problems to their drugs are less likely to continue the Key words treatment even when necessary for their health.9 The antidepressants, and his or her partner. consultation should include discussion of the patient’s antihypertensives, Encouraging a discussion with the patient sexual issues so these can be considered in treatment antipsychotics, arousal, about sexual function and providing erectile dysfunction, decisions. hypoactive sexual desire strategies to manage the problem are critical disorder, male impotence, to good clinical care.
    [Show full text]
  • Hyperkalemia Masked by Pseudo-Stemi Infarct Pattern and Cardiac Arrest Shareez Peerbhai1 , Luke Masha2, Adrian Dasilva-Deabreu1 and Abhijeet Dhoble1,2*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Peerbhai et al. International Journal of Emergency Medicine (2017) 10:3 International Journal of DOI 10.1186/s12245-017-0132-0 Emergency Medicine CASEREPORT Open Access Hyperkalemia masked by pseudo-stemi infarct pattern and cardiac arrest Shareez Peerbhai1 , Luke Masha2, Adrian DaSilva-DeAbreu1 and Abhijeet Dhoble1,2* Abstract Background: Hyperkalemia is a common electrolyte abnormality and has well-recognized early electrocardiographic manifestations including PR prolongation and symmetric T wave peaking. With severe increase in serum potassium, dysrhythmias and atrioventricular and bundle branch blocks can be seen on electrocardiogram. Although cardiac arrest is a worrisome consequence of untreated hyperkalemia, rarely does hyperkalemia electrocardiographically manifest as acute ischemia. Case presentation: We present a case of acute renal failure complicated by malignant hyperkalemia and eventual ventricular fibrillation cardiac arrest. Recognition of this disorder was delayed secondary to an initial ECG pattern suggesting an acute ST segment elevation myocardial infarction (STEMI). Emergent coronary angiography performed showed no evidence of coronary artery disease. Conclusions: Pseudo-STEMI patterns are rarely seen in association with acute hyperkalemia and are most commonly described with patient without acute cardiac symptomatology. This is the first such case presenting concurrently with cardiac arrest. A brief review of this rare pseudo-infarct pattern is also given. Keywords: Cardiac arrest, Hyperkalemia, Myocardial infarction, STEMI, ECG Background Case presentation Hyperkalemia that manifests with electrocardiographic A 27-year-old Caucasian male with a past medical his- findings of an ST segment elevation myocardial infarc- tory of hypertension presented to the emergency room tion (STEMI) is very rare.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact Or Fiction?
    Transplantation Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction? Stefanie Lam, Nilufar Partovi, Lillian SL Ting, and Mary HH Ensom he discovery and use of 4 classes of Timmunosuppressive agents (ie, cal- OBJECTIVE: To review the current clinical evidence on the effects of corticosteroid cineurin inhibitors, mammalian target of interactions with the immunosuppressive drugs cyclosporine, tacrolimus, myco- rapamycin [mTOR], antimetabolites, phenolate, and sirolimus. corticosteroids) have led to tremendous DATA SOURCES: Articles were retrieved through MEDLINE (1966–February 2008) improvements in short-term outcomes of using the terms corticosteroids, glucocorticoids, immunosuppressants, cyclo- solid organ transplantation. The goal of sporine, tacrolimus, mycophenolate, sirolimus, drug interactions, CYP3A4, P- glycoprotein, and UDP-glucuronosyltransferases. Bibliographies were manually immunosuppression is to prevent rejec- searched for additional relevant articles. tion of the transplanted organ while min- STUDY SELECTION AND DATA EXTRACTION: All English-language studies dealing imizing drug-related toxicity. The cal- with drug interactions between corticosteroids and cyclosporine, tacrolimus, cineurin inhibitors, cyclosporine and mycophenolate, and sirolimus were reviewed. tacrolimus, are potent inhibitors of T cells, DATA SYNTHESIS: Corticosteroids share common metabolic and transporter acting at a point of activation between re- pathways, the cytochrome P450 and P-glycoprotein (P-gp/ABCB1)
    [Show full text]
  • Medical Therapy for Pediatric Vascular Anomalies
    79 Medical Therapy for Pediatric Vascular Anomalies Judith F. Margolin, MD1 Heather Mills Soni, CPNP1 Sheena Pimpalwar, MD2 1 Baylor College of Medicine, Texas Children’sCancerandHematology Address for correspondence Judith F. Margolin, MD, Department of Service, Houston, Texas Pediatrics, Baylor College of Medicine, Texas Children’sCancerand 2 Division of Interventional Radiology, Department of Radiology, TCH, Hematology Service, Suite 1510, Clinical Care Center, 6701 Fannin Baylor College of Medicine, Houston, Texas Street, Houston, Texas 77030 (e-mail: [email protected]). Semin Plast Surg 2014;28:79–86. Abstract Vascular anomalies (VAs) comprise a large variety of individual diagnoses that in different phases of treatment require a diverse number of medical specialists to provide optimal care. Medical therapies include agents usually associated with cancer chemo- therapy, such as vincristine, as well more immunomodulatory types of drugs, such as Keywords glucocorticoids and sirolimus. These immunomodulating drugs are being successfully ► vascular anomalies applied in cases that are typically categorized as vascular tumors, including kaposiform ► chemotherapy hemangioendothelioma (KHE) and tufted angioma (TA), as well as some of the more ► sirolimus invasive types of vascular malformations (i.e., microcystic lymphatic malformations and ► kaposiform blue rubber bleb nevus syndrome (BRBNS). These therapies need to be combined with hemangio- good supportive care, which often involves anticoagulation, antimicrobial prophylaxis, endothelioma
    [Show full text]
  • Diapositiva 1
    4CPS-082 BACKGROUND: • Nephrogenic diabetes insipidus (NDI) results from the inability of the late distal tubules and collecting ducts to respond to vasopressin. • The lack of ability to concentrate urine results in polyuria and polidipsia. • NDI is almost always drug induced; however, there are other causes of it that are acquired, such as electrolyte abnormalities as hypokalemia or hypercalcemia. OBJECTIVE: • To describe a case of nephrogenic diabetes insipidus (NDI) associated with the long-term use and high-dose liposomal amphotericin B. METHODS: • Data were obtained from electronic medical records RESULTS: A 39 years old man diagnosed with diffuse large B-cell non-Hodgkin Lymphoma underwent an allogeneic bone marrow transplant. After a few months, the disease’s progression was detected and immunosuppressive treatment was suspended (February 2014). Rescue treatment was: Gemcitabine and Vinorelbine. In May, the patient was admitted to the hospital with graft-versus-host disease grade III, intestinal form. He was treated with: cyclosporine, micophenolate, sirolimus, methylprednisolone, oral and rectal beclametasone. Additionally, as antimicrobial prophylaxis were meropenem, acyclovir, levofloxacine, cotrimoxazole and caspofungine. In June, serum galactomannan antigen test was positive and invasive pulmonary aspergillosis was diagnosed. Aspergillus fumigatus and Aspergillus flavus were isolated. The patient was started on liposomal amphotericin B 6mg/kg (440 mg) daily during 41 days (accumulated dosage: 18.04g). Voriconazol was rejected because of concomitant treatment with sirolimus. During the treatment, his serum potassium was decreased <1.5mEq/L and it was difficult to maintain >3 mEq/L during the treatment with significant polyuria (urine output was >6litr/day). Nephrogenic diabetes insipidus(NDI) was diagnosed.
    [Show full text]
  • Sirolimus, Everolimus) Symptom Management Oxygen Rehab/Exercise Antidepressants/Anxiolytics Inhalers Lung Transplant Roadmap
    Drug Therapy for LAM Maryl Kreider, MD Director, ILD Program, Penn Lung Center, Philadelphia, PA (Drug) Therapy For LAM Disease Modifying MTOR inhibitors (sirolimus, everolimus) Symptom Management Oxygen Rehab/exercise Antidepressants/Anxiolytics Inhalers Lung transplant Roadmap Sirolimus What is it? Why in LAM? Nuts and Bolts Old therapies Future therapies Sirolimus Rapamycin = Rapamune = Sirolimus First of a class of medications called mTOR inhibitors Discovered in a soil sample on Easter Island – initially used as an antibiotic Now most common use is as a immunosuppressant in patients who have had transplants Also used in heart stents to stop them from getting clogged and as a cancer therapy (kidney cancer and some lymphomas) Sirolimus mTOR is an enzyme that lives in human cells and is part of a long and complex chain of interactions that control cell growth Blocking mTOR should reduce the growth of cells that are rapidly dividing Taveira-DaSilva and Moss. Rev Port Pneumol. Doesn’t kill the cells – 2012;18:142-4 just slows growth Sirolimus Other mTOR inhibitors Everlimus (Affinitor) Temsirolimus SIROLIMUS IN LAM Why sirolimus? Tuberous sclerosis complex is a genetic disorder with know abnormalities of TSC1 and TSC2 genes that lead to abnormal TSC1 and 2 proteins Some patients with TSC develop LAM We know that TSC1 and 2 stimulate the mTOR enzyme So the theory was if you block mTOR perhaps you would effect LAM CAST Trial Cincinnati Angiomyolipoma Sirolimus Trial (CAST) Looked at the effect of taking sirolimus for a year on the size of the AMLs (kidney growths) CAST Bissler et al.
    [Show full text]
  • Electrolyte Disorders and Arrhythmogenesis
    Cardiology Journal 2011, Vol. 18, No. 3, pp. 233–245 Copyright © 2011 Via Medica REVIEW ARTICLE ISSN 1897–5593 Electrolyte disorders and arrhythmogenesis Nabil El-Sherif1, Gioia Turitto2 1State University of NY, Downstate Medical Center and NY Harbor VA Healthcare System, Brooklyn, NY, USA 2Methodist University Hospital, Brooklyn, NY, USA Abstract Electrolyte disorders can alter cardiac ionic currents kinetics and depending on the changes can promote proarrhythmic or antiarrhythmic effects. The present report reviews the mecha- nisms, electrophysiolgical (EP), electrocardiographic (ECG), and clinical consequences of elec- trolyte disorders. Potassium (K+) is the most abundent intracellular cation and hypokalemia is the most commont electrolyte abnormality encountered in clinical practice. The most signifcant ECG manifestation of hypokalemia is a prominent U wave. Several cardiac and + non cardiac drugs are known to suppress the HERG K channel and hence the IK, and especially in the presence of hypokalemia, can result in prolonged action potential duration and QT interval, QTU alternans, early afterdepolarizations, and torsade de pointes ventricu- lar tachyarrythmia (TdP VT). Hyperkalemia affects up to 8% of hospitalized patients mainly in the setting of compromised renal function. The ECG manifestation of hyperkalemia de- pends on serum K+ level. At 5.5–7.0 mmol/L K+, tall peaked, narrow-based T waves are seen. At > 10.0 mmol/L K+, sinus arrest, marked intraventricular conduction delay, ventricular techycardia, and ventricular fibrillation can develop. Isolated abnormalities of extracellular calcium (Ca++) produce clinically significant EP effects only when they are extreme in either direction. Hypocalcemia, frequently seen in the setting of chronic renal insufficiency, results in prolonged ST segment and QT interval while hypercalcemia, usually seen with hyperparathy- roidism, results in shortening of both intervals.
    [Show full text]
  • Medical Term Lay Term(S)
    MEDICAL TERM LAY TERM(S) ABDOMINAL Pertaining to body cavity below diaphragm which contains stomach, intestines, liver, and other organs ABSORB Take up fluids, take in ACIDOSIS Condition when blood contains more acid than normal ACUITY Clearness, keenness, esp. of vision - airways ACUTE New, recent, sudden ADENOPATHY Swollen lymph nodes (glands) ADJUVANT Helpful, assisting, aiding ADJUVANT Added treatment TREATMENT ANTIBIOTIC Drug that kills bacteria and other germs ANTIMICROBIAL Drug that kills bacteria and other germs ANTIRETROVIRAL Drug that inhibits certain viruses ADVERSE EFFECT Negative side effect ALLERGIC REACTION Rash, trouble breathing AMBULATE Walk, able to walk -ATION -ORY ANAPHYLAXIS Serious, potentially life threatening allergic reaction ANEMIA Decreased red blood cells; low red blood cell count ANESTHETIC A drug or agent used to decrease the feeling of pain or eliminate the feeling of pain by general putting you to sleep ANESTHETIC A drug or agent used to decrease the feeling of pain or by numbing an area of your body, local without putting you to sleep ANGINA Pain resulting from insufficient blood to the heart (ANGINA PECTORIS) ANOREXIA Condition in which person will not eat; lack of appetite ANTECUBITAL Area inside the elbow ANTIBODY Protein made in the body in response to foreign substance; attacks foreign substance and protects against infection ANTICONVULSANT Drug used to prevent seizures ANTILIPIDEMIC A drug that decreases the level of fat(s) in the blood ANTITUSSIVE A drug used to relieve coughing ARRHYTHMIA Any change from the normal heartbeat (abnormal heartbeat) ASPIRATION Fluid entering lungs ASSAY Lab test ASSESS To learn about ASTHMA A lung disease associated with tightening of the air passages ASYMPTOMATIC Without symptoms AXILLA Armpit BENIGN Not malignant, usually without serious consequences, but with some exceptions e.g.
    [Show full text]